Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOther Accumulated ExpensesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bioregenx (BRGX) Non-Current Debt (2021 - 2025)

Bioregenx has reported Non-Current Debt over the past 5 years, most recently at $181825.0 for Q4 2025.

  • For Q4 2025, Non-Current Debt fell 28.59% year-over-year to $181825.0; the TTM value through Dec 2025 reached $181825.0, down 28.59%, while the annual FY2025 figure was $181825.0, 28.59% down from the prior year.
  • Non-Current Debt for Q4 2025 was $181825.0 at Bioregenx, down from $1.2 million in the prior quarter.
  • Over five years, Non-Current Debt peaked at $1.2 million in Q3 2025 and troughed at $150000.0 in Q1 2024.
  • A 5-year average of $522705.8 and a median of $254606.0 in 2024 define the central range for Non-Current Debt.
  • Biggest five-year swings in Non-Current Debt: crashed 51.57% in 2024 and later surged 659.16% in 2025.
  • Year by year, Non-Current Debt stood at $197837.0 in 2021, then fell by 1.02% to $195811.0 in 2022, then soared by 168.46% to $525681.0 in 2023, then tumbled by 51.57% to $254606.0 in 2024, then dropped by 28.59% to $181825.0 in 2025.
  • Business Quant data shows Non-Current Debt for BRGX at $181825.0 in Q4 2025, $1.2 million in Q3 2025, and $1.2 million in Q2 2025.